Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Inclusion Criteria: * Signed informed consent. * Completed the SH-NEN-0003 study with relief of upper GI symptom. Relief is defined as "last 7 days with a diary assessment of None or Minimal, but allowing up to 2 days to be rated as Mild during the 7-day period". * A clinical diagnosis of a chronic condition (e.g., osteoarthritis or rheumatoid arthritis) that requires continuous daily NSAID treatment for at least 6 months. Daily NSAID treatment is defined as taking the prescribed dose for at least 5 of 7 days in any given week and can include COX-2 selective NSAIDs, multiple NSAIDs, and high-dose NSAIDs. * Daily NSAID treatment dose and type: * Must have been stable for at least 9 weeks prior to inclusion * Are expected to remain stable for the duration of the study. * Must be administered orally. If more than one type of NSAID treatment is used, at least one type must be administered orally. * Hp negative on Histology performed at baseline endoscopy in the study SHNEN-0003. Exclusion Criteria: * Discontinuation from study SH-NEN-0003 * Pain, discomfort or burning in the upper abdomen precipitated by exercise or relieved by defecation. * Pain, discomfort or burning in the upper abdomen not associated with the use of NSAIDs, including COX-2 selective NSAIDs. * Pregnancy or lactation. Women of childbearing potential must maintain effective contraception during the study period as judged by the investigator.